Download MendeleyIdentification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.
Dorsch, D., Schadt, O., Stieber, F., Meyring, M., Gradler, U., Bladt, F., Friese-Hamim, M., Knuhl, C., Pehl, U., Blaukat, A.(2015) Bioorg Med Chem Lett 25: 1597-1602
- PubMed: 25736998
- DOI: https://doi.org/10.1016/j.bmcl.2015.02.002
- Primary Citation of Related Structures:
4R1V, 4R1Y - PubMed Abstract:
In a high-throughput screening campaign for c-Met kinase inhibitors, a thiadiazinone derivative with a carbamate group was identified as a potent in vitro inhibitor. Subsequent optimization guided by c-Met-inhibitor X-ray structures furnished new compound classes with excellent in vitro and in vivo profiles. The thiadiazinone ring of the HTS hit was first replaced by a pyridazinone followed by an exchange of the carbamate hinge binder with a 1,5-disubstituted pyrimidine. Finally an optimized compound, 22 (MSC2156119), with excellent in vitro potency, high kinase selectivity, long half-life after oral administration and in vivo anti-tumor efficacy at low doses, was selected as a candidate for clinical development.
Organizational Affiliation:
Merck Serono Research & Development, Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany. Electronic address: dieter.dorsch@merckgroup.com.
